- Coordination chemistry of thiazole-based ligands: New complexes generating 3D hydrogen-bonded architectures
-
The hydrothermal (solvothermal) reactions of ZnII, Co II, and CuII salts with the thiazole-based ligands 2-Htzc (thiazole-2-carboxylic acid), 4-Htzc (thiazole-4-carboxylic acid), and Htzc-py [2-(2-pyridyl)thiazole-4-carboxylic acid] led to the formation of coordination complexes with assorted geometry at the metal centers. The new complexes were characterized by conventional spectroscopic methods as well as by single-crystal X-ray analysis, TG-MS, and PXRD. Crystallographic studies have shown that an extended supramolecular network is generated in the solid state through the formaton of hydrogen bonds between the several polar groups present in the complex frameworks.
- Rossin, Andrea,Di Credico, Barbara,Giambastiani, Giuliano,Gonsalvi, Luca,Peruzzini, Maurizio,Reginato, Gianna
-
-
Read Online
- NEAR-INFRARED-RAY-ABSORBING COMPOSITION, NEAR-INFRARED-RAY CUT FILTER USING SAME, MANUFACTURING METHOD THEREFOR, CAMERA MODULE, AND MANUFACTURING METHOD THEREFOR
-
Provided are a near-infrared-ray-absorbing composition having strong near-infrared shielding properties when a cured film is produced, a near-infrared-ray cut filter, a manufacturing method therefor, a camera module, and a manufacturing method therefor. The near-infrared-ray-absorbing composition includes a copper complex obtained by reacting a compound (A) having at least two coordination sites with a copper component.
- -
-
Paragraph 0822; 0824; 0825
(2017/01/02)
-
- CARBOXYLATION CATALYSTS
-
The use of a complex of the form Z—M—OR in the carboxylation of a substrate is described. The group Z is a two-electron donor ligand, M is a metal and OR is selected from the group consisting of OH, alkoxy and aryloxy. The substrate may be carboxylated at a C—H or N—H bond. The metal M may be copper, silver or gold. The two-electron donor ligand may be a phosphine, a carbene or a phosphite ligand. Also described are methods of manufacture of the complexes and methods for preparing isotopically labelled caboxylic acids and carboxylic acid derivatives.
- -
-
Paragraph 0093
(2013/04/13)
-
- Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors
-
This invention relates to compounds of Formula (I) wherein Cy1, L1, Y, R1, L2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions.
- -
-
Page/Page column 40
(2012/04/23)
-
- Carboxylation of C-H bonds using N -heterocyclic carbene gold(I) complexes
-
A highly efficient [(NHC)AuI]-based (NHC = N-heterocyclic carbene) catalytic system for the carboxylation of aromatic and heteroaromatic C-H bonds was developed. The significant base strength of the Au-OH species is at the origin of the activation process and permits the facile functionalization of C-H bonds without the use of other organometallic reagents.
- Boogaerts, Ine I. F.,Nolan, Steven P.
-
supporting information; experimental part
p. 8858 - 8859
(2010/08/21)
-
- (DIHYDRO)IMIDAZOISO[5,1-A]QUINOLINES
-
The invention relates to imidazoiso[5,1-a]quinoline and 5,6-dihydro-imidazoiso[5,1-a]quinoline derivatives according to general Formula I or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility.
- -
-
Page/Page column 21
(2010/12/31)
-
- ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
-
Bipiperidyl compounds of the formula: (I) are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.
- -
-
Page/Page column 75
(2008/12/06)
-
- BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
-
Bipiperidinyl compounds of the formula I, are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.
- -
-
Page/Page column 73
(2008/12/07)
-
- Indane modulators of glucocorticoid receptor, AP-1, and/or NF/kB activity and use thereof
-
Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases having the structure of formula (I): or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is -A1QA2-; Q is a bond, —C(═O)—, —OC(O)—, —C(═O)NR5—, —SOp—, —SOpNR5—, —C(O)O—, —NR5C(O)—, —OC(O)NR5—, —NR5C(O)O—, —S(O)pNR5C(O)—, —C(O)NR5S(O)p— —NR5S(O)p—, or —NR5C(═O)NR6—. Y is selected from hydrogen, C1-4alkyl, OR16, substituted C1-6alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A1 and A2 are independently selected from a bond, C1-3alkylene, or C1-3alkenylene, and R1-R11 are defined herein. Also provided are pharmaceutical compositions, combinations, and methods of treating obesity, diabetes and inflammatory- or immune-associated diseases comprising said compounds.
- -
-
Page/Page column 49
(2008/06/13)
-
- MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
-
Non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) or an enantiomer, a diastereomer, a pharmaceutically acceptable salt, or hydrate thereof, where J is selected from NR1 or C(R4)(R4a); K is selected from NR2 or C(R5)(R5a); L is selected from NR3 or C(R6)(R6a); and A, X, Y, R1, R2, R3, R4, R4a, R5, R5a, R6, R6a, R8, R10, R11, and n are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.
- -
-
Page/Page column 128-129
(2010/11/25)
-
- ANTIPARASITIC TERPENE ALKALOIDS
-
The present invention relates to novel terpene alkaloids and their use as antiparasitic agents. The present invention also relates to an antiparasitic agent which comprises a terpene alkaloid compound of this invention as an effective ingredient in an antiparasitic formulation. More particularly, the present invention relates to derivatives of the terpene alkaloid (1S,2R,4aS,5R,8R,8aR)-2-(acetyloxy)-8a-hydroxy-3,8-dimethyl-5-(1-methylethenyl)-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl (2S,3aR,9bR)-6-chloro-9b-hydroxy-5-methyl-1,2,3,3a,5,9b-hexahydropyrrolo[2,3-c][2,1]benzoxazine-2-carboxylate. Pharmaceutical compositions comprising the same are also disclosed.
- -
-
Page 173-174
(2008/06/13)
-
- Epothilone analogs
-
Epothilone A, epothilone B, analogs of epothilone and libraries of epothilone analogs are synthesized. Epothilone A and B are known anticancer agents that derive their anticancer activity by the prevention of mitosis through the induction and stabilization of microtubulin assembly. The analogs of epothilone are novel. Several of the anlogs are demonstrated to have a superior cytotoxic activities as compared to epothilone A or epothilone B as demonstrated by their enhanced ability to induce the polymerization and stabilization of microtubules.
- -
-
-
- Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
-
Compounds having utility as anti-inflammatory agents in general and, more specifically, for the prevention and/or treatment of immunoinflammatory and autoimmune diseases are disclosed. The compounds are pyrimidine-containing compounds and, in one embodiment, are esters of the same. Methods are also disclosed for preventing and/or treating inflammatory conditions by administering to an animal in need thereof an effective amount of a compound of this invention, preferably in the form of a pharmaceutical composition.
- -
-
-
- Carboxyalkenamidocephalosporins
-
An antibacterial 7beta-(carboxyalkenoyl)amino-3-cephem-4-carboxylic acid represented by the following formula: STR1 (wherein R is aryl or a heterocyclic group; R1 is hydrogen or halogen; R2 is a single bond, alkylene, or thiaalkylene; R3 is a hydrogen atom or carboxy modifying group; R4 is hydrogen or methoxy; R5 is hydrogen or a 3-substituent of cephalosporins; R6 is a hydrogen atom or carboxy modifying group; and X is oxygen, sulfur, or sulfinyl) a pharmaceutical composition containing the same, and a method for treating a bacterial infection with the same.
- -
-
-